Choroba niebieskiego jezyka - szczepienia profilaktyczne w Europie

• Autorzy: Niedbalski W , Kesy A.

Warianty tytułu

EN

Bluetongue - prophylactic vaccinations in Europe

• Języki publikacji: PL

Abstrakty

EN

The article reviews the history, present status and the future of Bluetongue BT vaccines and prophylactic vaccinations against BT in Europe. To date, attenuated (modified live viruses, MLV) and inactivated virus preparations vaccines against BTV serotypes 2 and 4 were developed and used in the field. Moreover, virus-like particles (VLPs) produced from recombinant baculovirus and live recombinant vaccinia or canarypox virus-vectored vaccines were tested in the laboratory. The main aims of BT vaccination strategy are as follows: to prevent clinical disease, the reduction of the spread of the BT virus in the environment and to safeguard the movement of susceptible animals between affected and free zones. The mass vaccinations of all susceptible animals are the most efficient veterinary method to fight against BT and a harmonized strategy for vaccinations in Europe would improve the intra-Community trade of live animals. The amount of BT vaccines needed for the protection of the European livestock exceed 220 million doses, including about 150 million doses of BTV serotype 8. In January 2008, the Intervet International B.V., as the first vaccine producer, has developed a vaccine against BTV serotype 8 for sheep and cattle and declared the delivery of the first quantities of vaccine on the European trade in May 2008. The BT eradication policy combining administrative methods and prophylactic vaccination of all susceptible animals, completed with application of insecticides - pesticides to control Culicoides midges in the environment - is currently the most effective method of fighting against BT.

Słowa kluczowe

PL

Europa; owce; kozy; bydlo; choroby zwierzat; choroba niebieskiego jezyka; profilaktyka; szczepienia ochronne; szczepionki atenuowane; szczepionki inaktywowane; szczepionki rekombinowane

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2009
• Tom: 65
• Numer: 02
• Opis fizyczny: s.79-83,tab.,bibliogr.

Twórcy

autor

Niedbalski W

• Panstwowy Instytut Weterynaryjny - Panstwowy Instytut Badawczy w Pulawach, Zaklad Pryszczycy, ul.Wodna 7, 98-220 Zdunska Wola

autor

Kesy A.

Bibliografia

• 1.Boone J. D., Balasurriya U. B., Karaca K., Audonnet J. C., Yao J., He L., Nordgren R., Monaco F., Savini G., Gardner I. A., Maclachlan N. J.: Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 2007, 25, 672-678.
• 2.Breard E., Pozzi N., Sailleau C., Durand B., Catinot V., Sellem E., Dumont P., Guerin B., Zientara S.: Transient adverse effect of the attenuated bluetongue virus vaccine on the quality of the ram semen. Vet. Rec. 2007, 160, 431-435.
• 3.Di Emidio B., Nicolussi P., Patta C., Ronchi G. F., Monaco F., Savini G., Ciarelli A., Caporale V.: Efficacy and safety studies on an inactivated vaccine against bluetongue virus serotype 2. Vet. Ital. 2004, 40, 640-644.
• 4.Dungu B., Gerdes T., Smith T.: The use of vaccination in the control of bluetongue in southern Africa. Vet. Ital. 2004, 40, 616-622.
• 5.Erasmus B.: Bluetongue in sheep and goats. Aust. Vet. J. 1975, 51, 165-170.
• 6.Jimenez-Clavero M. A., Aguero M., Miguel E. S., Mayoral T., Lopez M. C., Ruano M. J., Romero E., Monaco F., Polci A., Savini G., Gomez-Tejedor C.: High throughput detection of bluetongue virus by a new real-time fluorogenic reverse transcription-polymerase chain reaction: Application on clinical samples from current Mediterranean outbreaks. J. Vet. Diagn. Invest. 2006, 18, 7-17.
• 7.Lobato Z. I., Coupar B. E., Gray C. P., Lunt R., Andrew M. E.: Antibody responses and protective immunity to recombinant vaccinia virus - expressed bluetongue virus antigens. Vet. Immunol. Immunopathol. 1997, 59, 293-3-9.
• 8.MacLachlan N. J., Osburn B. I., Scott J. L., Ghalib H. W.: Orbivirus infection of the bovine fetus. Prog. Clin. Biol. Res. 1985, 178, 79-84.
• 9.MAPA. Report of efficacy test performed in Spain with different commercially available vaccine against BTV4 in cattle and sheep. MAPA report, 2006.
• 10.Monaco F., Bonfini B., Zaghini M., Antonucci D., Pini A., Savini G.: Vaccination of cattle using monovalent modified-live vaccine against bluetongue virus serotype 2: innocuity, immunogenicity, and effect on pregnancy. Vet. Ital. 2004, 40, 671-675.
• 11.Monaco F., Camma C., Serini S., Savini G.: Differentiation between field and vaccine strain of bluetongue virus serotype 16. Vet. Microbiol. 2006, 116, 45-52.
• 12.Niedbalski W.: Application of real-time reverse transcription polymerase chain reaction assay for the detection of bluetongue virus. Bull. Vet. Inst. Pulawy 2008, 52, 189-193.
• 13.Niedbalski W., Kęsy A.: Seroprevalence of antibodies against bluetongue virus in the animals imported to Poland from the EU countries. Polish J. Vet. Sci. 2008, 11, 205-208.
• 14.Niedbalski W., Kęsy A.: Występowanie przeciwciał przeciwko wirusowi choroby niebieskiego języka w surowicy zwierząt sprowadzonych do Polski. Medycyna Wet. 2008, 64, 76-79.
• 15.Roy P.: Genetically engineered structure-based vaccine for bluetongue disease. Vet. Ital. 2004, 40, 594-600.
• 16.Roy P., French T., Erasmus B. J.: Protective efficacy of virus-like particles for bluetongue disease. Vaccine 1992, 10, 28-32.
• 17.Savini G., Monaco F., Calistri P., Panichi G., Ruiu A., Leone A., Caporale V.: Neutralising antibody response in cattle after vaccination with monovalent modified-live vaccine against bluetongue virus serotype 2. Vet. Ital. 2004, 40, 668-670.
• 18.Savini G., Monaco F., Citarella R., Calzetta G., Panichi G., Ruiu A., Caporale V.: Monovalent modified-live vaccine against bluetongue virus serotype 2: immunity studies in cows. Vet. Ital. 2004, 40, 664-667.
• 19.Savini G., Monaco F., Conte A., Migliaccio P., Casaccia C., Salucci S., Di Ventura M.: Virological and serological response of sheep following field vaccination with bivalent modified-live vaccine against bluetongue virus serotypes 2 and 9. Vet. Ital. 2004, 40, 631-634.
• 20.Savini G., Monaco F., Facchinei A., Pinoni C., Salucci S., Cofini F., Di Ventura M.: Field vaccination of sheep with bivalent modified-live vaccine against bluetongue virus serotypes 2 and: effect on milk production. Vet. Ital. 2004, 40, 627-630.
• 21.Savini G., MacLachlan N. J., Sanchez-Vizcaino J.-M., Zientara S.: Vaccines against bluetongue in Europe. Comp. Immunol. Microbiol. Infect. Dis. 2008, 31, 101-120.
• 22.Trębas M., Smreczak M., Orłowska A., Żmudziński J. F.: Epizootiologia choroby niebieskiego języka. Medycyna Wet. 2007, 63, 1273-1276.
• 23.Wade-Evans A. M., Romero C. H., Mellor P., Takamatsu H., Anderson J., Thevasagayam J., Fleming M. J., Mertens P. P., Black D. N.: Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology 1996, 220, 227-2231.
• 24.Wijaszka T., Truszczyński M.: Występowanie na świecie w latach 2006-2007 ważnych epizootii, według OIE. Medycyna Wet. 2007, 63, 1270-1272.